Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
Pharmacovigilance01:19

Pharmacovigilance

805
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
805
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Therapeutic Index01:13

Therapeutic Index

4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE.

Circulation. Population health and outcomes·2026
Same author

Unmet needs poststroke and associated factors: A systematic review and meta-analysis.

Rehabilitation psychology·2026
Same author

PERKS-International: A Randomized Controlled Trial Testing the Efficacy of an mHealth Application to Reduce Risk Factors for the Primary Prevention of Stroke.

Stroke·2026
Same author

Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke.

Stroke·2026
Same author

Statistical analysis plan for Love Your Brain: a multi-arm randomised controlled trial of a stroke prevention digital platform.

Trials·2026
Same author

Antibiotic use in older Australians with and without dementia in primary care.

Age and ageing·2026
Same journal

Feasibility of early double sequential defibrillation in out-of-hospital cardiac arrest: the double-D randomised pilot trial.

Heart (British Cardiac Society)·2026
Same journal

Correspondence on 'When a patent foramen ovale becomes pathological' by Saji and Ohara.

Heart (British Cardiac Society)·2026
Same journal

Cost-effectiveness of N-terminal pro-B-type natriuretic peptide thresholds for echocardiography referral in primary care heart failure management.

Heart (British Cardiac Society)·2026
Same journal

Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis.

Heart (British Cardiac Society)·2026
Same journal

Importance of rating: the impact of establishing age and sex normative values for left ventricular strain rate.

Heart (British Cardiac Society)·2026
Same journal

Man in his 40s with palpitations.

Heart (British Cardiac Society)·2026
查看所有相关文章

相关实验视频

Updated: Jun 18, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

阿司匹林:最新的证据和发展.

Mark R Nelson1, J Andrew Black2

  • 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia Mark.Nelson@utas.edu.au.

Heart (British Cardiac Society)
|July 29, 2024
PubMed
概括
此摘要是机器生成的。

阿司匹林最初是一种抗炎药物,现在是主要心血管不良事件 (MACE) 的关键预防药物. 目前正在进行的研究正在探索其在癌症化学预防和其他疾病中的未来潜力.

关键词:
心血管疾病心血管疾病治疗结果治疗结果

更多相关视频

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.7K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K

相关实验视频

Last Updated: Jun 18, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

2.7K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 心血管医学 心血管医学
  • 在瘤学瘤学.

背景情况:

  • 阿司匹林是一种基础药物,最初是用于治疗疼痛和炎症的.
  • 后来发现,它可以有效地预防主要不良心血管事件 (MACE).
  • 目前用于预防MACE的阿司匹林在MACE率下降和竞争性疗法的人群中对其疗效/安全概况进行了评估.

研究的目的:

  • 审查阿司匹林在疾病预防中的既定和新兴作用.
  • 讨论阿司匹林在心血管和瘤化学预防中使用的不断变化的临床背景.
  • 突出正在进行的临床研究,调查阿司匹林未来的治疗应用.

主要方法:

  • 对阿司匹林药理性质和临床应用的文献综述.
  • 对主要心血管不良事件的流行病学趋势的分析.
  • 检查当前的治疗替代方案和癌症化学预防的新兴研究.

主要成果:

  • 阿司匹林仍然是预防重大心血管不良事件 (MACE) 的重要药物.
  • 它的疗效和安全平衡在当代人群中至关重要,MACE发病率正在下降.
  • 新兴研究表明,阿司匹林在癌症化学预防和辅助治疗中可能发挥作用.

结论:

  • 阿司匹林的实用性超出其抗炎原点,扩展到心血管事件预防.
  • 未来阿司匹林的临床相关性将受到其与竞争性治疗方法的性能及其在新疾病领域的潜力的影响.
  • 持续的临床研究对于全面定义阿司匹林未来的治疗场景至关重要,包括其在癌症预防中的作用.